Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
Titel:
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
Auteur:
Ettl, J. Quek, R.G.W. Lee, K.-H. Rugo, H.S. Hurvitz, S. Gonçalves, A. Fehrenbacher, L. Yerushalmi, R. Mina, L.A. Martin, M. Roché, H. Im, Y.-H. Markova, D. Bhattacharyya, H. Hannah, A.L. Eiermann, W. Blum, J.L. Litton, J.K.